Standout Papers

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with ad... 2009 2026 2014 2020 570
  1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial (2009)
    Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology

Immediate Impact

3 from Science/Nature 85 standout
Sub-graph 1 of 18

Citing Papers

Oesophageal cancer
2024 Standout
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
1 intermediate paper

Works of Gerhard Förster being referenced

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009 Standout

Author Peers

Author Last Decade Papers Cites
Gerhard Förster 741 25 34 370 303 24 1.0k
Javier Gutiérrez Santamarı́a 588 1 5 434 313 26 860
Gordana Verstovsek 249 3 11 366 499 28 990
Susanne Arbogast 563 35 390 368 26 1.4k
Czesław Osuch 674 3 147 494 27 978
Luisa Toffolatti 633 17 273 249 42 1.1k
Zeng-Feng Wang 664 1 30 343 394 17 1.2k
Isam Eltoum 497 2 522 439 26 1.2k
Akiko Ohashi 763 2 11 185 421 28 1.4k
Lori Rink 413 9 113 190 31 928
C Sakakura 307 13 265 362 28 975

All Works

Loading papers...

Rankless by CCL
2026